SecBot SecBot
PRESS-RELEASE ·Filed Mar 2, 2026

URGN

UroGen Pharma Ltd.
MIXED
Impact 6/10
Horizonweeks Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Traders should monitor ZUSDURI's post-J Code sales acceleration in Q1 2026 as a key indicator of commercial traction. While JELMYTO shows stable growth, ZUSDURI's uptake and future guidance will be critical for sentiment. The debt refinancing improves liquidity but adds long-term interest obligations. Pipeline catalysts (UGN-103 NDA in H2 2026, UGN-501 IND by end of 2026) could drive future upside.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$19.02
T+0 close · Mar 2, 2026 · via day close
Latest settled
+54.89%
T+60 · $29.46
Vs SPY
+45.56%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 2 $19.02entry
  2. T+1 · 9mo ago −1.05%α −0.14% · $18.82
  3. T+5 · 8mo ago +4.68%α +5.89% · $19.91
  4. T+20 · 8mo ago −10.62%α −2.68% · $17.00
  5. T+60 · 6mo ago +54.89%α +45.56% · $29.46
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

UroGen Pharma reported full-year 2025 financial results with total revenue of $109.8 million, up 21% YoY, driven by the commercial launch of ZUSDURI ($15.8M in sales) and 7% underlying growth in JELMYTO sales ($94M). The company refinanced its debt with Pharmakon Advisors for $200M in non-dilutive capital, strengthening its balance sheet. Despite higher R&D and SG&A expenses, management expressed confidence in ZUSDURI's launch trajectory following the January 2026 effective J Code, and provided 2026 JELMYTO sales guidance of $97M–$101M.

Key Financial Metrics

Revenue
$109.8M
+21.0% YoY
EPS
$-3.19
Guidance
Not provided for ZUSDURI; JELMYTO: $97M–$101M
maintained
Deal Value
$200.0M

Key Facts

  • ZUSDURI achieved $15.8 million in net sales in 2025, its first full year post-FDA approval (June 2025).
  • JELMYTO generated $94.0 million in 2025, reflecting 7% year-over-year underlying demand growth.
  • Total revenue increased 21% YoY to $109.8 million in 2025.
  • Net loss widened to $153.5 million ($3.19/share) in 2025 from $126.9 million ($2.96/share) in 2024.
  • Cash, cash equivalents, and marketable securities declined to $120.5 million as of December 31, 2025, from $241.7 million a year earlier.
  • Company secured $200 million refinancing from Pharmakon Advisors, with a $50 million accordion option, at 8.25% fixed interest, repayment starting Q1 2030.
  • 2026 JELMYTO sales guidance: $97M–$101M (3–7% growth); no ZUSDURI sales guidance provided.
  • 2026 operating expense guidance: $240M–$250M, including $20M–$24M in share-based compensation.
  • Phase 3 UTOPIA trial for UGN-103 showed 77.8% three-month complete response rate; NDA planned for H2 2026.

Financial Impact

Revenue grew 21% to $109.8M in 2025, but net loss increased to $153.5M. Operating expenses to remain elevated in 2026 at $240M–$250M. JELMYTO expected to grow modestly by $3M–$7M in 2026.

revenuenet_lossoperating_expensescash_positiondebt_structure

Risk Factors

  • ZUSDURI is in early launch phase with limited sales visibility; reimbursement and adoption may lag expectations.
  • Cash position decreased by over 50% YoY to $120.5M, raising potential future financing needs despite new debt.
  • Operating losses are widening despite revenue growth, reflecting high commercial and R&D investments.
  • Forward-looking statements dominate messaging; actual performance may fall short of management's optimistic tone.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3247313

Track record

16 reports on URGN

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +54.89% at T+60 after the Mar 2, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $25.90 Now $28.10 +8.49% settles Nov 23
  2. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  3. Nov 4, 202612d ago Press Release Bearish 6/10 Entry $28.74 to $26.10 Now $28.10 +2.23% ▲ +9.19% +8.27% vs SPY
  4. Nov 2, 202614d ago Press Release Neutral 4/10 Entry $34.36 to $26.31 Now $28.10 −18.22% ▼ −23.43% −23.51% vs SPY
  5. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $33.75 to $28.74 Now $28.10 −16.74% ▼ −14.84% −14.13% vs SPY
  6. Oct 19, 202628d ago Press Release Bullish 6/10 Entry $34.15 to $34.23 Now $28.10 −17.72% ▲ +0.23% +0.38% vs SPY
  7. Oct 9, 20265w ago 144 Neutral 2/10 Entry $36.83 to $34.56 Now $28.10 −23.70% ▼ −6.16% −4.20% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $45.00 to $43.04 Now $28.10 −37.56% ▼ −4.36% −4.02% vs SPY
  9. Aug 20, 202612w ago 8-K Neutral 4/10 Entry $46.80 to $45.50 Now $28.10 −39.96% ▼ −2.78% −3.89% vs SPY
  10. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $46.43 to $49.00 Now $28.10 −39.48% ▲ +5.54% +5.18% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 2, 2026